Note: Descriptions are shown in the official language in which they were submitted.
CA 02952759 2016-12-16
WO 2016/008997
PCT/EP2015/066321
A method and a device for determining a body fluid glucose level of a patient,
and
a computer program product
The present disclosure refers to a method and a system for determining a body
fluid glucose
level a patient, and a computer program product.
Background
Medical devices are often used as diagnostic devices and / or therapeutic
devices in diagnos-
ing and / or treating medical conditions of patients. For example, a blood
glucose meter is
used as a diagnostic device to measure blood glucose levels of patients
suffering from diabe-
tes. An insulin infusion pump is used as a therapeutic device to administer
insulin to patients
suffering from diabetes.
Diabetes mellitus, often referred to as diabetes, is a chronic condition in
which a person has
elevated glucose levels that result from defects in the body's ability to
produce and/or use in-
sulin. There are three main types of diabetes. Type 1 diabetes can be
autoimmune, genetic,
and/or environmental and usually strikes children and young adults. Type 2
diabetes accounts
for 90 to 95% of diabetes cases and is linked to obesity and physical
inactivity. Gestational
diabetes is a form of glucose intolerance diagnosed during pregnancy and
usually resolves
spontaneously after delivery.
Diabetes is managed primarily by controlling the level of glucose in the
blood. This level is
dynamic and complex, and is affected by multiple factors including the amount
and type of
food consumed, and the amount of insulin (which mediates transport of glucose
across cell
membranes) in the blood. Glucose levels are also sensitive to exercise, sleep,
stress, smoking,
travel, illness, menses, and other psychological and lifestyle factors unique
to individual pa-
tients. The dynamic nature of blood glucose and insulin, and all other factors
affecting blood
glucose, often require a person with diabetes to forecast blood glucose
levels. Therefore, ther-
apy in the form of insulin or oral medications, or both, can be timed to
maintain blood glucose
levels in an appropriate range.
CA 02952759 2016-12-16
WO 2016/008997 - 2 -
PCT/EP2015/066321
Management of diabetes is time-consuming for patients because of the need to
consistently
obtain reliable diagnostic information, follow prescribed therapy, and manage
lifestyle on a
daily basis. Diagnostic information, such as blood glucose, is typically
obtained from a capil-
lary blood sample with a lancing device and is then measured with a handheld
blood glucose
meter. Interstitial glucose levels may be obtained from a continuous glucose
sensor worn on
the body.
A handheld device may receive patient information from a number of different
sources, such
as an insulin pump, a continuous glucose monitor, a computer program, user
input, etc. In
order to accurately utilize this information, the handheld device may need to
calibrate the in-
formation received from these sources. For example, a handheld diabetes
managing device
may receive, from a continuous glucose monitor, raw data that is related to a
glucose level of
a patient. In order to make use of this raw data, the handheld diabetes
managing device may
need to be calibrated to correlate the received raw data with a measured blood
glucose level of
the patient. The accuracy of this calibration can affect the care and
treatment of the patient.
Accordingly, there is a need for a method of calibrating a handheld diabetes
managing device
to determine an accurate estimated glucose level of a patient from data
received from a con-
tinuous glucose monitor.
A variety of implantable electrochemical sensors has been proposed for
detecting specific
analysts or compositions in a patient's blood. For instance, glucose sensors
are provided for
use in obtaining an indication of blood glucose levels in a patient. Such
readings are useful in
monitoring a treatment regime which typically includes regular administration
of insulin. Sen-
sor signals provided by the sensor device are processed for determining the
actual glucose
level. In document EP 1 154 718 B1 use of a regression is proposed for
correlating sensor
signals representing measurement data with the actual blood glucose level.
Document US 6,326,160 B1 discloses methods, systems, and devices for measuring
the con-
centration of a target analyte presented in a biological system using a series
of measurements
obtained from a monitoring system and a Mixtures of Expert (MOE) algorithm. A
method for
measuring blood glucose in a subject is disclosed.
CA 02952759 2016-12-16
=
3
Document WO 2012 / 084157 Al refers to a method for calibrating a handheld
diabetes man-
aging device based on data generated by a continuous glucose monitor. The
method can include
sampling a current of the continuous glucose monitor at a sampling interval
over a time period
to generate a plurality of current samples for the time period. The method can
also include
determining a mean, median and standard deviation of the plurality of current
samples. The
blood glucose level of the patient can be measured at a first time and a
calibration equation that
associates the plurality of current samples with the estimated glucose level
of the patient based
on the measured blood glucose level and the plurality of current samples can
be determined
when the standard deviation is less than a first threshold and an absolute
value of a difference
between the mean and median is less than a second threshold.
From document US 2012 / 0191362 Al a method for operating measuring equipment
for de-
tecting an analyte in a bodily fluid by means of a continuously measuring
blood glucose sensor
is disclosed. A calibration method is carried out for the prospective
calibration of the measuring
equipment. At least three calibration points are detected in the calibration
method, wherein each
calibration point comprises a measurement signal form the measuring equipment
and a refer-
ence value of an associated reference measurement. A plurality of possible
slopes is established
between the calibration points. At least on robust estimation method, using a
formation of at
least one median is used to determine a probable slope from the plurality of
possible slopes.
Furthermore, a measurement is carried out. During the measurement and using
the probable
slope, a concentration of the analyte in the bodily fluid is deduced from a
measurement signal
from the measuring equipment and the probable slope.
Document US 2007 / 0038053 Al discloses a method for continuously measuring
the concen-
tration of target chemical analytes present in a biological system, and
processing analyte-spe-
cific signals to obtain a measurement value that is closely correlated with
the concentration of
the target chemical analyte in the biological system. A raw measurement signal
is processed in
a conversion step in order to remove or correct for background information
present in the signal.
One such background signal is the baseline background. Baseline background
interferes with
the measurement of the analyte of interest. The baseline background may vary
with time. In ad-
dition, electrochemically active interfering species and / or residual analyte
can be present in
the device which will further interfere with measurement of the analyte of
interest.
CA 02952759 2016-12-16
=
=
3A
It has been considered that drug interference may potentially mask serious
condition in the glu-
cose level of a body fluid (Tang et al.: "Effects of Drugs on Glucose
Measurements with
handheld glucose meters and a portable glucose analyzer", Clinical Chemistry,
2000; 113, pages
75-86).
Document US 2013 / 0338628 Al refers to a system including a processor and at
least one
memory configured to provide a response determinator. The response
determinator may receive
therapeutic and wellness data. Moreover, the response determinator may
determine a response
based on the received therapeutic and wellness data. The response may
represent a reaction to
a substance integrated with an ingestible event marker. The determined
response may be pro-
vided to, for example, a therapy controller.
Document US 2013 / 0297222 Al discloses methods and apparatus that permit an
analyte con-
centration to be estimated from a measurement in the presence of compounds
that interfere with
the measurement.
Document US 2012 / 0191362 Al discloses a method for operating measuring
equipment for
detecting an analyte in a bodily fluid by means of a continuously measuring
blood glucose
sensor. A calibration method is carried out for the prospective calibration of
the measuring
equipment.
Document US 2014 / 0138261 Al refers to methods and systems to apply a
plurality of test
voltages to the test strip and measure a current transient output resulting
from an electrochemi-
cal reaction in a test chamber of the test strip so that an estimated
interferent value can be de-
termined so that such interferent value can be used to correct the current
transients at specific
time points for more accurate glucose concentration determination.
Document US 2010 / 0292932 Al refers to a method and an apparatus for
estimating the fea-
tures of target materials by using kinetic change information along time, when
measuring the
result of a chemical reaction between two materials, target materials and
reactant, with an opti-
cal or electrochemical method.
CA 02952759 2016-12-16
=
3B
Summary
It is an object to provide a method and a system which provide for determining
a body fluid
glucose level of a patient from a continuous signal of a glucose sensor
element of a continuous
body fluid glucose monitoring device in an efficient and reliable manner.
According to an aspect, a method for determining a body fluid glucose level of
a patient from
a continuous signal of a glucose sensor element of a continuous body fluid
glucose monitoring
device in a data processing unit, comprising receiving measurement data
representing a contin-
uous sensor signal provided by a glucose sensor element of a continuous body
fluid glucose
monitoring device in the data processing unit, receiving calibration data
representing a time-
dependent zero-signal level of the glucose sensor element in the data
processing unit, determin-
ing a body fluid glucose level by processing at least the measurement data and
the calibration
data in the data processing unit, the processing comprising subtraction of the
time dependent
zero-signal level from the continuous sensor signal, and providing result data
indicative of the
continuous body fluid glucose level in the processing unit, characterized in
that the receiving
calibration data comprises receiving calibration data representing a time-
dependent zero-signal
level comprising time-dependent inteferent signal contributions representing a
presence of an
interferent in the body fluid for which the body fluid glucose level is
determined, wherein the
interferent is a substance different from glucose and the sensor element is
responsive to the
interferent in the body fluid is provided.
According to another aspect, a system for determining a body fluid glucose
level of a patient
from a continuous signal of a glucose sensor element of a continuous body
fluid glucose mon-
itoring device, the system comprising a data processing unit configured to
receive measurement
data representing a continuous sensor signal provided by a glucose sensor
element of a contin-
uous body fluid glucose monitoring device, receive calibration data
representing a time-depend-
ent zero-signal level of the glucose sensor element, determine a body fluid
glucose level by
processing at least the measurement data and the calibration data in the data
processing unit,
the processing comprising subtraction of the time dependent zero-signal level
from the contin-
uous sensor signal, and provide result data indicative of the body fluid
glucose level in the
processing unit, characterized in that the receiving calibration data
comprises receiving calibra-
tion data representing a time dependent zero-signal level comprising time-
dependent interferent
CA 02952759 2016-12-16
=
3C
signal contributions representing a presence of an interferent in the body
fluid for which the
body fluid glucose level is determined, wherein the interferent is a substance
different from
glucose and the sensor element is responsive to the interferent in the body
fluid is provided.
Also, a computer program product for determining a body fluid glucose level of
a patient from
a continuous signal of a glucose sensor element of a continuous body fluid
glucose monitoring
device in a data processing unit, comprising means recorded on an electronic
data carrier for
receiving measurement data representing a continuous sensor signal provided by
a glucose sen-
sor element of a continuous body fluid glucose monitoring device in the data
processing unit,
means recorded on the electronic data carrier for receiving calibration data
representing a time-
dependent zero-signal level of the glucose sensor element in the data
processing unit, means
recorded on the electronic data carrier for determining a body fluid glucose
level by processing
at least the measurement data and the calibration data in the data processing
unit, the processing
comprising subtraction of the time dependent zero-signal level from the
continuous sensor sig-
nal, and means recorded on the electronic data carrier for providing result
data indicative of the
continuous body fluid glucose level in the processing unit, characterized in
that the receiving
calibration data comprises receiving calibration data representing a time
dependent zero-signal
level comprising time-dependent interferent signal contributions representing
a presence of an
interferent in the body fluid for which the body fluid glucose level is
determined, wherein the
interferent is a substance different from glucose and the sensor element is
responsive to the
interferent in the body fluid is provided.
According to an aspect, a method for determining a body fluid glucose level of
a patient from
a continuous signal of a glucose sensor element of a continuous body fluid
glucose monitoring
device in a data processing unit is provided. In the data processing unit
measurement data are
received, the measurement data are representing a continuous sensor signal
provided by a glu-
cose sensor element of a continuous body fluid glucose monitoring device in
the data processing
unit. The glucose sensor element may be configured for subcutaneous access,
e.g. a measure-
ment in the interstitium. Further, in the data processing unit calibration
data are received, the
calibration data representing a time-dependent zero-signal level of the
glucose sensor element.
A glucose level of a body fluid is determined by processing at least the
measurement data and
the calibration data in the data processing unit. In the step of processing
the calibration data
representing the time dependent zero-signal level are subtracted from the
continuous sensor
CA 02952759 2016-12-16
4
signal. Result data indicative of the glucose level of the body fluid are
provided in the pro-
cessing unit, which may be independent of an additional blood glucose
reference.
According to another aspect, a system for determining a body fluid glucose
level of a patient
from a continuous signal of a glucose sensor element of a continuous body
fluid glucose mon-
itoring device is provided. The system comprising a data processing unit
configured to receive
measurement data representing a continuous sensor signal provided by a glucose
sensor element
of a continuous body fluid glucose monitoring device, receive calibration data
representing a
time-dependent zero-signal level of the glucose sensor element, determine a
continuous glucose
level of a body fluid by processing at least the measurement data and the
calibration data in the
data processing unit, the processing comprising subtraction of the time
dependent zero-signal
level from the continuous sensor signal, and provide result data indicative of
the continuous
glucose level of the body fluid in the processing unit.
The zero-signal level of the glucose sensor element being different from a
zero output (an output
which is zero - no detectable signal) is indicative of a sensor output signal
contribution in re-
sponse to a substance other than glucose in the body fluid under
investigation.
The body fluid under investigation may be, for example, one of interstitial
fluid, blood, and
urea.
CA 02952759 2016-12-16
The receiving the calibration data comprise receiving calibration data
representing a zero-signal
level comprising an interferent signal contribution indicative of presence of
at least one inter-
ferent in the body fluid for which the glucose level is determined. The
glucose sensor element
is responsive to the presence of the interferent (interfering substance) in
the body fluid under
5 investigation. In conclusion, with respect to the electrical output
signal of the glucose sensor
element there is signal interference affecting the zero-signal level.
The interferent signal contribution is a time-dependent interferent signal
contribution. As an
alternative, the interferent signal contribution may not dependent on time
which may also be
referred to as a constant interferent signal contribution.
The receiving calibration data may comprise receiving calibration data
representing a kinetic
course of decomposition of an interferent in the body fluid for which the
glucose level is deter-
mined. The kinetic course of decomposition may represent an (additional)
interferent signal
contribution with respect to its time dependence and / or its expected time-
dependent signal
height at the output of the glucose sensor element.
The receiving calibration data may comprise receiving an event starting input
indicative of a
starting time of the presence of the interferent in the body fluid for which
the glucose level is
determined. Together with the kinetic course of decomposition of the
interferent this infor-
mation may be used for calibrating the sensor signals received from the
glucose sensor element.
In the method for determining the glucose level, the receiving calibration
data may comprise
generating a prompting signal for calibration data input. By the prompting
signal the user may
be requested to provide input of the calibration data.
The generating the prompting signal may comprise receiving a user selection
input. For exam-
ple, the user may select calibration data input from some external or internal
storage medium.
The processing unit may be provided in one of a handheld body fluid glucose
management
device, and a continuous body fluid glucose measurement device. In some
embodiments, the
CA 02952759 2016-12-16
WO 2016/008997 - 6 -
PCT/EP2015/066321
processing unit may be provided in one of a handheld blood glucose management
device, a
continuous blood glucose measurement device, a handheld interstitial fluid
management de-
vice, and a continuous interstitial fluid glucose measurement device.
With respect to the system for determining the glucose level of a body fluid
of a patient, the
embodiments described above with reference to the method may apply
accordingly.
According to another aspect, not necessarily to be combined with the method or
the system
for determining the body fluid glucose level of a patient, a method for
determining a pharma-
cokinetic curve for an active substance or composition in a body fluid from a
continuous sen-
sor signal of a glucose sensor element of a continuous body fluid glucose
monitoring device
in a data processing unit may be provided. In the processing unit first
measurement data are
received, the first measurement data are representing a continuous sensor
signal provided by a
glucose sensor element of a continuous body fluid glucose monitoring device.
The glucose
sensor element may be configured for subcutaneous access. The glucose sensor
element may
be configured for interstitial fluid or blood measurement. In the data
processing unit further
data, for example, second measurement data are provided, the further data
representing a sen-
sor signal provided from a further body fluid glucose monitoring different
from the continu-
ous body fluid glucose monitoring device. The further body fluid glucose
monitoring may
also be from the continuous body fluid glucose monitoring type. The first
measurement data
and the further data are processed for determining a pharmacokinetic curve of
an active sub-
stance or composition causing time-dependent signal interference for the first
measurement
data. The further data are not interfered by signal contribution of the active
substance. There-
fore, a pharmacokinetic curve can be determined from processing of the first
measurement
data and the further data. If the first measurement data and the further data
represent the same
glucose level of a patient, but measured independently, the pharmacokinetic
curve may simp-
ly be determined by subtracting the further data from the first measurement
data. Surprisingly,
the measurements for determining body fluid glucose level may be used for
determining ki-
netic behavior of an active substance or composition in the body fluid.
In general, the method may also be performed by using measured data from a
sensor element
providing signals indicative of another analyte, such as lactate, present in
the body fluid under
investigation. The body fluid may be, for example, one of interstitial fluid,
blood, and urea. At
CA 02952759 2016-12-16
WO 2016/008997 - 7 -
PCT/EP2015/066321
least two independent sources for data (e.g. measurement with the active
component present,
and measurement with no presence of the active component) need to be analyzed.
One or
more steps of the method may be combined with the method or the system for
determining the
body fluid glucose level of a patient provided in the present disclosure. Also
one or more
steps of the method or the system for determining the body fluid glucose level
of a patient
may be combined with the method for determining a pharmacokinetic curve for an
active sub-
stance or composition in a bodily fluid.
The data used in the method for determining the pharmacokinetic curve for an
active sub-
stance or composition in a body fluid from the continuous sensor signal of the
glucose sensor
element of the continuous body fluid glucose monitoring at least in a part may
be taken from
a calibration process performed for the device. Different calibration methods
may be applied,
e.g. by comparing calibration with a constant offset and calibration with a
calibrated offset.
Description of embodiments
Following, embodiments, by way of example, are described with reference to
figures. In the
figures show:
Fig. 1 a schematic representation of a patient and a treating clinician,
Fig. 2 a schematic representation of a patient with a continuous glucose
monitor (CGM),
ambulatory durable insulin infusion pump, ambulatory non-durable insulin
infusion
pump, and diabetes manager,
Fig. 3 a schematic representation of a diabetes care system,
Fig. 4 a functional block diagram of a diabetes manager,
Fig. 5 a functional block diagram of a continuous glucose body fluid,
Fig. 6 a block diagram of a method for determining a body fluid glucose level
of a patient
from continuously measured sensor signals of a glucose sensor element, and
Fig. 7 graphical representation of time-dependent curves, and
Fig. 8 a block diagram of a method for determining a body fluid glucose level
of a patient
from continuously measured sensor signals of a glucose sensor element.
Referring now to Fig. 1, a person 100 with diabetes and a healthcare
professional 101 are
shown in a clinical environment. Persons with diabetes include persons with
metabolic syn-
CA 02952759 2016-12-16
WO 2016/008997 - 8 -
PCT/EP2015/066321
drome, pre-diabetes, type 1 diabetics, type 2 diabetics, and gestational
diabetics and are col-
lectively referred to as a patient. Healthcare providers for diabetes are
diverse and include
nurses, nurse practitioners, physicians, and endocrinologists and are
collectively referred to as
a clinician.
During a healthcare consultation, the patient 100 typically shares with the
clinician 101 a va-
riety of patient data including blood glucose measurements, continuous glucose
monitor data,
amounts of insulin infused, amounts of food and beverages consumed, exercise
schedules,
and other lifestyle information. The clinician 101 can obtain additional
patient data that in-
cludes measurements of HbAl C, cholesterol levels, triglycerides, blood
pressure, and weight
of the patient 100. The patient data can be recorded manually or
electronically on a handheld
diabetes managing device 102, a diabetes analysis software executed on a
personal computer
(PC) 106, and / or a web-based diabetes analysis site (not shown). The
clinician 101 can ana-
lyze the patient data manually or electronically using the diabetes analysis
software and/or the
web-based diabetes analysis site. After analyzing the patient data and
reviewing adherence of
the patient 100 to previously prescribed therapy, the clinician 101 can decide
whether to mod-
ify the therapy for the patient 100.
Referring now to Fig. 2, the patient 100 can use a continuous glucose monitor
(CGM) 200, an
ambulatory durable insulin infusion pump 201 or an ambulatory non-durable
insulin infusion
pump 202 (collectively insulin pump 201 or 202), and the handheld diabetes
managing device
102 (hereinafter the diabetes manager 102). The CGM 200 uses a subcutaneous
sensor to
sense and monitor the amount of glucose in the subcutaneous fluid of the
patient 100 and
communicates corresponding readings to the handheld diabetes managing device
102.
The diabetes manager 102 performs various tasks including measuring and
recording blood
glucose levels, determining an amount of insulin to be administered to the
patient 100 via the
insulin pump 201 or 202, receiving patient data via a user interface,
archiving the patient data,
etc. The diabetes manager 102 periodically receives readings from the CGM 200
indicating a
glucose level in the subcutaneous fluid of the patient 100. The diabetes
manager 102 transmits
instructions to the insulin pump 201 or 202, which delivers insulin to the
patient 100. Insulin
can be delivered in the form of a bolus dose, which raises the amount of
insulin in the blood
of the patient 100 by a predetermined amount. Additionally, insulin can be
delivered in a
CA 02952759 2016-12-16
WO 2016/008997 - 9 -
PCT/EP2015/066321
scheduled manner in the form of a basal dose, which maintains a predetermined
insulin level
in the blood of the patient 100.
Referring now to Fig. 3, a diabetes management system 300 used by the patient
100 and the
clinician 101 includes one or more of the following devices: the diabetes
manager 102, the
continuous glucose monitor (CGM) 200, the insulin pump 201 or 202, a mobile
device 301,
the diabetes analysis software on the PC 103, and other healthcare devices
302. The diabetes
manager 102 is configured as a system hub and communicates with the devices of
the diabe-
tes management system 300. Alternatively, the insulin pump 202 or the mobile
device 301
can serve as the system hub. Communication between the various devices in the
diabetes
management system 300 can be performed using wireless interfaces (e.g.,
Bluetooth) and / or
wireline interfaces (e.g., USB). Communication protocols used by these devices
can include
protocols compliant with the IEEE 11073 standard as extended using guidelines
provided by
Continua® Health Alliance Design Guidelines. Further, healthcare records
systems such
as Microsoft® HealthVault.TM. and Google.TM. Health can be used by the
patient 100
and clinician 101 to exchange information.
The diabetes manager 102 can receive glucose readings from one or more sources
(e.g., from
the CGM 200). The CGM 200 continuously measures the glucose level of the
patient 100.
The CGM 200 periodically communicates the glucose level to the diabetes
manager 102. The
diabetes manager 102 and the CGM 200 communicate wirelessly using a
proprietary wireless
protocol.
Additionally, the diabetes manager 102 includes a blood glucose meter (BGM)
and a port that
communicates with the BGM (both not shown). The port can receive a blood
glucose meas-
urement strip 303. The patient 100 deposits a sample of blood or other bodily
fluid on the
blood glucose measurement strip 303. The BGM analyzes the sample and measures
the blood
glucose level in the sample. The blood glucose level measured from the sample
and/or the
blood glucose level read by the CGM 200 can be used to determine the amount of
insulin to
be administered to the patient 100.
The diabetes manager 102 communicates with the insulin pump 201 or 202. The
insulin pump
201 or 202 can be configured to receive instructions from the diabetes manager
102 to deliver
CA 02952759 2016-12-16
WO 2016/008997 - 10 -
PCT/EP2015/066321
a predetermined amount of insulin to the patient 100. Additionally, the
insulin pump 201 or
202 can receive other information including meal and/or exercise schedules of
the patient 100.
The insulin pump 201 or 202 can determine the amount of insulin to administer
based on the
additional information.
The insulin pump 201 or 202 can also communicate data to the diabetes manager
102. The
data can include amounts of insulin delivered to the patient 100,
corresponding times of de-
livery, and pump status. The diabetes manager 102 and the insulin pump 201 or
202 can
communicate using a wireless communication protocol such as Bluetooth. Other
wireless or
wireline communication protocols can also be used.
In addition, the diabetes manager 102 can communicate with other healthcare
devices 302.
For example, the other healthcare devices 302 can include a blood pressure
meter, a weight
scale, a pedometer, a fingertip pulse oximeter, a thermometer, etc. The other
healthcare devic-
es 302 obtain and communicate personal health information of the patient 100
to the diabetes
manager 102 through wireless, USB, or other interfaces. The other healthcare
devices 302 use
communication protocols compliant with ISO/IEEE 11073 extended using
guidelines from
Continual® Health Alliance. The diabetes manager 102 can communicate with
the other
healthcare devices 302 using interfaces including Bluetooth, USB, etc.
Further, the devices of
the diabetes management system 300 can communicate with each other via the
diabetes man-
ager 102.
The diabetes manager 102 can communicate with the PC 103 using Bluetooth, USB,
or other
interfaces. A diabetes management software running on the PC 103 includes an
analyzer-
configurator that stores configuration information of the devices of the
diabetes management
system 300. The configurator has a database to store configuration information
of the diabetes
manager 102 and the other devices. The configurator can communicate with users
through
standard web or computer screens in non-web applications. The configurator
transmits user-
approved configurations to the devices of the diabetes management system 300.
The analyzer
retrieves data from the diabetes manager 102, stores the data in a database,
and outputs analy-
sis results through standard web pages or computer screens in non-web based
applications.
CA 02952759 2016-12-16
WO 2016/008997 - 11 -
PCT/EP2015/066321
The diabetes manager 102 can communicate with the mobile device 301 using
Bluetooth. The
mobile device 301 can include a cellular phone, a PDA, or a pager. The
diabetes manager 102
can send messages to an external network through the mobile device 301. The
mobile device
301 can transmit messages to the external network based on requests received
from the diabe-
tes manager 102.
In some embodiments, the CGM 200 measures the level of glucose in the
interstitial fluid of
the patient 100 by sampling a current. The level of glucose in the
interstitial fluid, and there-
fore the sampled current, is related to the glucose level of the patient 100.
In order to accurate-
ly estimate the glucose level of the patient 100 based on the interstitial
fluid glucose level
measured by the CGM 200, the diabetes manager 102 can be periodically
calibrated.
The diabetes manager 102 can be calibrated by determining a calibration
equation based on at
least one current sample and at least one blood glucose measurement. The
current sampled by
the CGM 200 and the blood glucose level of the patient 100 can be assumed to
have a linear
relationship within a normal measurement region of approximately 40 to 400
Milligrams per
Deciliter. Based on this assumed linear relationship, the calibration equation
can be a linear
equation that associates one or more current samples with an estimated glucose
level of the
patient. After calibration, the diabetes manager 102 can determine an
estimated glucose level
of the patient 100 based on the calibration equation and the current sampled
by the CGM 200.
Referring now to Fig. 4, an exemplary diabetes manager 102 includes a blood
glucose meas-
uring (BGM) module 400, a communication module 401, a user interface module
402, user
interfaces 403, a processing module 404, memory 405, and a power module 406.
The user
interface module 402 and the processing module 404 can be implemented by an
application
processing module 407. The BGM module 400 includes a blood glucose measuring
engine
that analyzes samples provided by the patient 100 on the blood glucose
measurement strip
303 and that measures the amount of blood glucose in the samples. The
communication mod-
ule 401 can include multiple radios that communicate with different devices of
the diabetes
management system 300. The user interface module 402 connects the diabetes
manager 102
to various user interfaces 403 that the patient 100 can use to interact with
the diabetes manag-
er 102. For example, the user interfaces 403 can include keys, switches, a
display, a speaker, a
microphone, a secure digital (SD) card port, and / or a USB port (all not
shown).
CA 02952759 2016-12-16
WO 2016/008997 - 12 -
PCT/EP2015/066321
The processing module 404 processes data received from the BGM module 400, the
commu-
nication module 401, and the user interface module 402. The processing module
404 uses
memory 405 for processing and storing data. The memory 405 can include
volatile and non-
volatile memory. The processing module 404 outputs data to and receives data
from the user
interfaces 403 via the user interface module 402. The processing module 404
outputs data to
and receives data from the devices of the diabetes management system 300 via
the communi-
cation module 401. The power module 406 supplies power to the components of
the diabetes
manager 102. The power module 406 can include a rechargeable battery or other
source of
power. The battery can be recharged, e.g., by using an adapter that plugs into
a wall outlet
and/or via a USB port on the diabetes manager 102.
Referring now to Fig. 5, an exemplary continuous glucose monitor (CGM) 200
includes a
sensor 500, a communication module 501, a processing module 502, memory 503,
and a
power module 504. The sensor 500 can monitor a condition of the patient 100
that is related
to the glucose level of the patient 100. For example, the sensor 500, alone or
in combination
with processing module 502, can periodically sample a current value that
corresponds to the
level of glucose in the interstitial fluid of the patient 100. The
communication module 501 can
include one or more radios that communicate with different devices of the
diabetes manage-
ment system 300.
The processing module 502 processes data received from the sensor 500 and the
communica-
tion module 501. The processing module 502 uses memory 503 for processing and
storing
data. The memory 503 can include volatile and nonvolatile memory. The
processing module
502 outputs data to and receives data from the devices (for example, diabetes
manager 102) of
the diabetes management system 300 via the communication module 501. The power
module
504 supplies power to the components of the CGM 200. In some embodiments, the
power
module 504 includes a battery or other source of power. The source of power
may include a
battery that can be recharged, e.g., by using an adapter that plugs into a
wall outlet.
Referring to Fig. 6, an exemplary method 600 for determining a continuous body
fluid glu-
cose level of a patient is illustrated. The method 600 begins at step 601
where in a data pro-
cessing unit measurement data are received. The data processing unit, for
example, may be
CA 02952759 2016-12-16
WO 2016/008997 - 13 -
PCT/EP2015/066321
provided in the handheld diabetes management device 102 or the continuous
glucose monitor
200. The processing module 404 or 502 may be provided with the data processing
unit. The
measurement data received are indicative of a continuous sensor signal
provided by a glucose
sensor element such as sensor 500.
In step 602 calibration data are received in the data processing unit, the
calibration data are
representing a time dependent zero-signal level of the glucose sensor element
used for detect-
ing the continuous sensor signal. The zero-signal level of the glucose sensor
element is differ-
ent from a zero output (an output which is actually zero; non-detectable
signal) and may be
indicative of a sensor output signal contribution in response to one or more
active substances
other than glucose in the bodily fluid (blood) under investigation. In step
603 a continuous
blood glucose level is determined by processing at least the measurement data
and the calibra-
tion data in the data processing unit, such processing comprising subtraction
of the zero-signal
level from the continuous sensor signal provided by the glucose sensor
element. Sensor signal
contributions caused by any substance different from glucose are deleted
afterwards. Such
signal processing may be considered as being (part of) a calibration.
The calibration data may represent a zero-signal level comprising an
interferent signal contri-
bution indicative of presence of at least one interferent in the body fluid
for which the glucose
level is determined. For example, the patient may have taken aspirin the time-
dependent de-
composition which may cause time-dependent sensor signal contribution.
Information as to
the time dependence of the decomposition of aspirin, for example, may be taken
from C. Bo-
gentoft, et al.: Influence of Food on the Absorption of Acetylsalicylic Acid
from Enteric-
Coated Dosage Forms, Europ. J. din. Pharmacol. 14, 351-355 (1978).
The glucose sensor element is responsive to the presence of the interferent
(interfering sub-
stance) in the body fluid under investigation, e.g. blood or interstitial
fluid. In conclusion,
with respect to the electrical output signal of the glucose sensor element
there is signal inter-
ference affecting the zero-signal level.
For the purpose of further explanation, Fig. 7a to 7d show time depend signal
curves derived
from a simulation. Referring to Fig. 7a, a time dependent continuous sensor
signal represent-
ing a signal of a glucose sensor, e.g. a current signal, is shown for which a
signal interference
CA 02952759 2016-12-16
WO 2016/008997 - 14 -
PCT/EP2015/066321
started at a time of 2800 min. The simulated time dependence of the
interfering signal is
shown in Fig. 7b.
In Fig. 7c curve A represents a continuous glucose level without correction
derived from the
sensor signal curve in Fig. 7a. Curve B represents the corrected continuous
glucose level de-
rived by subtracting the interferent signal. Finally, Fig. 7d shows the
difference between curve
A and B in Fig. 7c. Such curve represents a pharmacokinetic course of the
interferent compo-
sition in the body fluid under investigation. Within the noise level of the
sensor element by
which the signals are detected, Fig. 7d resembles the curve in Fig. 7b.
Referring to Fig. 8, an exemplary method 800 for determining a pharmacokinetic
curve for an
active substance or composition in a body fluid from a continuous sensor
signal of a glucose
sensor element of a continuous body fluid glucose monitoring device in a data
processing unit
is illustrated. The method 800 begins at step 801 where, in the processing
unit, first measure-
ment data are received, the first measurement data are representing a
continuous sensor signal
provided by a glucose sensor element of a continuous body fluid glucose
monitoring device.
The glucose sensor element may be configured for subcutaneous access. The data
processing
unit, for example, may be provided in the handheld diabetes management device
102 or the
continuous glucose monitor 200. The processing module 404 or 502 may be
provided with the
data processing unit. The measurement data received are indicative of a
continuous sensor
signal provided by a glucose sensor element such as sensor 500.
In step 802, in the data processing unit, second measurement data are
provided, the second
measurement data representing a sensor signal provided from a further body
fluid glucose
monitoring different from the continuous body fluid glucose monitoring device.
The further
body fluid glucose monitoring may also be from the continuous body fluid
glucose monitor-
ing type. The first and second measurement data are processed for determining
a pharmacoki-
netic curve of an active substance or composition causing time-dependent
signal interference
for the first measurement data. The second measurement data are not interfered
by signal con-
tribution of the active substance. Therefore, a pharmacokinetic curve can be
determined from
processing of the first and second measurement data (step 803). If the first
and second meas-
urement data represent the same glucose level of a patient, but measured
independently, the
pharmacokinetic curve may simply be determined by subtracting the second
measurement
CA 02952759 2016-12-16
WO 2016/008997 - 15 -
PCT/EP2015/066321
from the first measurement data. Surprisingly, the measurements for
determining body fluid
glucose level may be used for determining kinetic behavior of an active
substance or compo-
sition in the bodily fluid.
In general, the method 800 may also be performed by using measured data from a
sensor ele-
ment providing signals indicative of another analyte, such as lactate, present
in the body fluid
under investigation. The body fluid may be different from blood, e.g. urea or
interstitial fluid.
At least two independent measurements (measurement with the active component
present;
measurement with no presence of the active component) need to be analyzed. One
or more
steps of the method 800 may be combined with the method 600 or the system for
determining
the body fluid glucose level of a patient provided in the present disclosure.
Also one or more
steps of the method 600 or the system for determining the body fluid glucose
level of a patient
may be combined with the method 800 for determining the pharmacokinetic curve
for an ac-
tive substance or composition in a body fluid.
